Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 390

Gastroenterology

  • Home
  • Gastroenterology
Headache Relief Shampoo Voted #1 Best New Product in 2019

Dr. D’s Medicated Headache Relief Shampoo is now available. This medicated shampoo will help alleviate headaches simply by soaking it on your head. Finding relief from minor to severe headaches shouldn’t always involve reaching for a bottle of pills. Dr. D is here to give you another option. Our proprietary formula will leave your head feeling better.

BUY NOW! http://headachereliefshampoo.com/product/headache-relief-shampoo/

January 1, 2019 / by / in
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
Conditions:   Advanced Solid Tumor;   NSCLC;   Melanoma;   Cervical Cancer;   Multiple Myeloma;   Lymphoma, Non-Hodgkin;   DLBCL;   Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma;   Esophageal Cancer
Interventions:   Drug: AB308;   Drug: Zimberelimab
Sponsor:   Arcus Biosciences, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 9, 2021 / by / in
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
Conditions:   Advanced Bile Duct Carcinoma;   Advanced Breast Carcinoma;   Advanced Cervical Carcinoma;   Advanced Endometrial Carcinoma;   Advanced Esophageal Carcinoma;   Advanced Gastric Carcinoma;   Advanced Head and Neck Carcinoma;   Advanced Lung Non-Small Cell Carcinoma;   Advanced Lung Small Cell Carcinoma;   Advanced Malignant Solid Neoplasm;   Advanced Ovarian Carcinoma;   Advanced Penile Carcinoma;   Advanced Pleural Malignant Mesothelioma;   Advanced Urothelial Carcinoma;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Anatomic Stage IV Breast Cancer AJCC v8;   Clinical Stage III Gastric Cancer AJCC v8;   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Pathologic Stage III Gastric Cancer AJCC v8;   Pathologic Stage IIIA Gastric Cancer AJCC v8;   Pathologic Stage IIIB Gastric Cancer AJCC v8;   Pathologic Stage IIIC Gastric Cancer AJCC v8;   Pathologic Stage IV Gastric Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Prognostic Stage IV Breast Cancer AJCC v8;   Stage III Cervical Cancer AJCC v8;   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Intrahepatic Bile Duct Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Penile Cancer AJCC v8;   Stage III Pleural Malignant Mesothelioma AJCC v8;   Stage IIIA Cervical Cancer AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Penile Cancer AJCC v8;   Stage IIIA Pleural Malignant Mesothelioma AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Cervical Cancer AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Penile Cancer AJCC v8;   Stage IIIB Pleural Malignant Mesothelioma AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IV Cervical Cancer AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Intrahepatic Bile Duct Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Pleural Malignant Mesothelioma AJCC v8;   Stage IVA Cervical Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVB Cervical Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Triple-Negative Breast Carcinoma;   Unresectable Urothelial Carcinoma
Interventions:   Drug: Cisplatin;   Drug: Elimusertib;   Drug: Gemcitabine Hydrochloride
Sponsor:   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 7, 2021 / by / in
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
Conditions:   Non-Erosive Gastro-Esophageal Reflux Disease;   Heartburn
Interventions:   Drug: Vonoprazan;   Drug: Placebo
Sponsor:   Phathom Pharmaceuticals, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 7, 2021 / by / in
MR-guided Pre-operative RT in Gastric Cancer
Condition:   Gastric Adenocarcinoma
Interventions:   Radiation: MR guided radiation therapy;   Procedure: Blood for ctDNA
Sponsors:   Washington University School of Medicine;   Viewray Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 6, 2021 / by / in
Continuous Glucose Monitoring to Reduce Hypoglycemia and Improve Safety in Patients With Hypoglycemia After Gastric Surgery
Conditions:   Hypoglycemia, Reactive;   Hypoglycemia
Intervention:   Device: Dexcom continuous glucose monitor
Sponsors:   Joslin Diabetes Center;   DexCom, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 27, 2021 / by / in
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
Condition:   Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
Intervention:   Drug: Trastuzumab deruxtecan
Sponsors:   AstraZeneca;   Daiichi Sankyo Co., Ltd.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 25, 2021 / by / in
A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
Conditions:   Breast Neoplasms;   Gastric Neoplasm;   Solid Tumors
Intervention:   Drug: ARX788
Sponsor:   Ambrx, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 23, 2021 / by / in
Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer
Condition:   Gastric Cancer
Interventions:   Other: Molecular testing for all participants.;   Other: Germline Testing;   Other: Survey
Sponsors:   The University of Texas Health Science Center at San Antonio;   Institute for Integration of Medicine & Science-UT Health San Antonio
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 17, 2021 / by / in
Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis
Conditions:   Gastric Cancer;   Peritoneal Carcinomatosis;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Drug: Paclitaxel;   Drug: Leucovorin;   Drug: Fluorouracil
Sponsor:   University of California, Irvine
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 10, 2021 / by / in
STRENGTH Expansion
Conditions:   Esophageal Cancer;   Gastroesophageal Junction Cancer
Intervention:   Other: STRENGTH
Sponsors:   University of Colorado, Denver;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 9, 2021 / by / in